After outcry, 4-year-old girl can stay in U.S. for lifesaving care
It was a routine Vargas had perfected through fear. Missing even one step could mean disaster, she said. But for the first time in months, she felt like she could finally breathe.
Vargas and her family, who hail from Mexico, could stay in the United States, the only country where her daughter can receive the complex and specialized treatment that keeps her alive. The girl has short bowel syndrome, a condition where the body cannot absorb enough nutrients from food.
The relief that washed over Vargas had come after nearly two excruciating months, she said. In April, the government had abruptly revoked the family's humanitarian parole without giving them a reason. The move triggered swift international outrage and prompted 38 Democratic members of Congress to send a letter to Homeland Security Secretary Kristi L. Noem urging her to reverse the decision.
Then on Tuesday, Vargas received a notice from U.S. Citizenship and Immigration Services: The family had been granted another year of parole.
'I felt more than tranquility — peace,' Vargas, 28, told The Washington Post. 'These moments of not knowing whether we'd be deported or allowed to stay were beyond overwhelming. It was horrible knowing that my daughter's ability to stay alive depended on this humanitarian parole.'
In a statement Friday, the Department of Homeland Security confirmed the family was approved to stay in the United States.
The agency did not respond to questions about why their parole had been revoked after initially being granted until July. Vargas's attorney, Gina Amato Lough, said the family fit into two categories of people who have seen their status canceled amid the Trump administration's crackdown on immigration: people with parole and those who entered the country through the Biden administration's CBP One app. The Trump administration has also rolled back humanitarian protections for hundreds of thousands of immigrants.
The girl, whom the family's lawyers identify by the pseudonym Sofia, was born in Playa del Carmen, Mexico, in fragile health. She had her first surgery at four days old for a malformation in her intestine. Four more surgeries followed, Vargas said, and left the girl with short bowel syndrome.
Soon, the girl was transferred to a hospital nearly 800 miles away in Mexico City. Vargas and her husband uprooted their lives to move close to the facility, which their daughter did not leave for two years.
After two more surgeries and a near-death experience, doctors told Vargas they were running out of options. The only thing left to try was an intestine transplant, which had never been done in that hospital before, Vargas recalled being told.
'They told me my child was most likely going to die,' she said.
Vargas refused to give up hope. She started researching transplants and alternative treatments in Spain and the United States, and contacting hospitals. At the same time, she prepared an application for humanitarian parole, which allows people to temporarily live in the United States for urgent humanitarian reasons.
In 2023, the family boarded a flight to Tijuana from Mexico City. They carried the girl — still connected to nutrition bags — to the border and legally entered the United States through an appointment secured through the CBP One app, Vargas said. They were granted humanitarian parole until July 2025.
The girl arrived in California as an emaciated toddler and was transported to a children's hospital in San Diego. She soon began to thrive under specialized care, Vargas said, including hours tethered to an intravenous feeding system — a machine that pumps nutrients into her through a tube.
Little by little, the child reached milestones — like sitting up and taking her first steps — that to Vargas had once seemed impossibly out of reach. She was transferred to Children's Hospital Los Angeles after a year.
In September, the girl was discharged and allowed to live something close to a normal life: playing in the park, painting with her father and attending day care while Vargas works in a buffet-style restaurant. She loves dancing, especially to 'Mambo No. 5' by Lou Bega.
'She feels the rhythm and starts moving her body,' Vargas said, laughing.
For a while, it felt like the family was moving forward. Then came the April 11 letter from DHS, giving them just seven days before their legal status would be revoked.
'Do not attempt to remain in the United States — the federal government will find you. Please depart the United States immediately,' read the email, which was reviewed by The Post.
The family received two more such notices. The last one, from May 13, warned Vargas that her work authorization had also been canceled.
'I can't explain the fear,' she said. 'Feeling like any time we were out on the streets someone was going to take us away and deport us.'
Adding to her anxiety, Vargas said, was the fact that her daughter's medical team had said the equipment that keeps the girl alive can't leave the country — and patients on this treatment aren't allowed to travel.
DHS denied in its statement that the family was 'actively being deported.'
Though the family hadn't been placed in removal proceedings or received a final deportation order, Amato Lough said the revocation of their status effectively left them undocumented. The letter the family received from DHS warned: 'If you do not depart the United States immediately you will be subject to potential law enforcement actions that will result in your removal.'
On May 14, Vargas and her family filed another application for humanitarian parole.
Weeks went by without an answer. Then, after the Los Angeles Times reported on the family's situation, USCIS contacted the family to begin scheduling biometrics appointments — a standard, early step in many immigration benefit applications. Days later, the family was told they would have status for a year.
'While we celebrate this victory, we cannot ignore the systemic challenges that brought [the girl] to the brink,' Amato Lough and her co-counsel, Rebecca Brown, said in a statement. 'Her parole was terminated without warning, and for weeks there was no functional avenue to alert USCIS that a child's life was in danger. It took an international outcry and pressure from elected officials to get a response — something that used to take a single phone call.'
In Bakersfield, Vargas rocked her daughter gently this week and whispered reassurances.
'She's so groggy,' she said, as the girl whined. 'But she's going to be okay.'
This time, she believed it.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale
AI heart failure diagnostics innovator makes it possible to catch deadly heart failure earlier by analyzing the most common heart scan in the world and proactively alerting clinicians FDA-cleared, reimbursed by Medicare, and live in top U.S. hospitals, Ultromics is now scaling nationwide to make early heart failure detection part of routine cardiac care, wherever patients get an echo Ultromics is trained on one of the largest real-world echo datasets globally and validated across 25 peer-reviewed studies, helping close one of medicine's most dangerous diagnostic gaps, where up to 64% of heart failure cases still go undetected OXFORD, England, July 31, 2025 /PRNewswire/ -- Ultromics, a pioneer in AI-driven cardiology solutions, today announced it has raised $55 million in Series C financing. The round was co-led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University. Major U.S. health systems, including UChicago Medicine's venture investment vehicle, UCM Ventures, and UPMC Enterprises also participated in the round. Built on years of clinical study and hundreds of thousands of echo scans, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect HFpEF and cardiac amyloidosis, two of the most elusive forms of heart failure. The company is now expanding across the U.S. to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup. Ultromics is also expanding its pipeline to include additional cardiac conditions, new distribution channels and deeper partnerships with health systems and clinical leaders. It's a critical moment for cardiovascular care. Heart failure is rising, costs are mounting and millions of patients are still going undiagnosed, especially those with harder-to-detect forms like HFpEF and cardiac amyloidosis. In the U.S. alone, heart failure drives over $30 billion in annual healthcare costs, a number projected to exceed $70 billion by 2030. Clinicians often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses even when patients are actively seeking care. In fact, up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or irreversible damage occurs. Ultromics addresses this diagnostic blind spot by using AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions—without requiring new hardware or disrupting clinical workflows. Its FDA-cleared EchoGo® platform supports diagnosis of HFpEF and cardiac amyloidosis. Trained and validated on one of the largest real-world echo datasets globally, EchoGo® generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo® is fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide. "The reality is, hospitals already have the data, they just haven't had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we're helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses," said Ross Upton, PhD, CEO and Founder, Ultromics. "We've spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis." Ultromics has already analyzed more than 430,000 echocardiograms to date. In clinical studies, EchoGo® improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The company's latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing disease from similar conditions. "Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies," said Alastair Stewart, Head of Investments, Venture Capital, at L&G. "This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year." With growing adoption and partnerships across flagship institutions, including UChicago Medicine, University Hospitals Cleveland, Northwestern, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the Midwest. Its platform is helping hospitals reduce unnecessary tests, streamline workflows and initiate treatment earlier so it's more effective and less expensive. "Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care," said Umur Hursever, Partner at Lightrock. "Ultromics' AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics' mission and growing impact." Ultromics has rapidly expanded its platform capabilities and U.S. market presence during the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed in 2025 by the launch of EchoGo® Score, a new feature that adds AI-driven probability scoring to EchoGo® Heart Failure, helping clinicians detect HFpEF with greater nuance. These clinical advances are now supported by Medicare reimbursement for both outpatient and inpatient use, strengthening Ultromics' foundation for scaled adoption across U.S. hospitals. "There's a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret," said Victor Westerlind, Managing Director at Allegis Capital. "What's exciting about Ultromics is how they're closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it's a diagnostic win that will help save lives." About Ultromics Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately—using nothing more than a standard ultrasound scan. Ultromics is backed by leading investors and U.S. healthcare systems and is on a mission to transform how heart disease is diagnosed and treated. For more, visit About Lightrock Lightrock is a global investment platform committed to building a sustainable future. Operating across private and public markets, Lightrock manages over $5.5 billion in assets and invests in Europe, North America, Latin America, Asia, and Africa. Lightrock is a certified B Corp with a dedicated team of over 130 professionals working across a network of six offices For more information, visit About L&G Established in 1836, L&G is one of the UK's leading financial services groups and a major global investor, with £1.1 trillion in total assets under management (as at FY24) of which c. 44% (c. £0.5 trillion) is international. We have a highly synergistic business model, which continues to drive strong returns. We are a leading player in Institutional Retirement, in Retail Savings and Protection, and in Asset Management through both public and private markets. Across the Group, we are committed to responsible investing and dedicated to serving the long-term savings and investment needs of customers and society. About Allegis Capital Allegis Capital is an early-stage venture capital firm partnering with companies that enable digital transformation across the enterprise. The firm supports founders with hands-on guidance, operational expertise, and access to a global network of industry leaders. With a long track record of building market-defining businesses, Allegis backs the teams and platforms reshaping how work gets done. Headquartered in Palo Alto, California, Allegis has been investing in enterprise innovation for over two decades. For more information, visit Photo - - View original content to download multimedia: SOURCE Ultromics Sign in to access your portfolio


Business Wire
25 minutes ago
- Business Wire
World FZO Brings Its 12th World Congress to Panama in 2026
DUBAI, United Arab Emirates--(BUSINESS WIRE)--The World Free Zones Organization announced the signing of a Memorandum of Understanding with the government of Panama to host the 12th annual World FZO's World Congress in the country's capital, Panama City, in July 2026. The MoU was signed by His Excellency Dr. Mohammed AlZarooni, Chairman of the World FZO, and His Excellency Julio Moltó, Minister of Commerce and Industries at the Government of the Republic of Panama, in the presence of senior officials from both sides. The announcement was made during an official visit led by Dr. AlZarooni to Panama City, where he met with His Excellency José Raúl Molino Quintero, President of the Republic of Panama. On the sidelines of the visit, the delegation toured key sites in Panama, including the Colón Free Trade Zone, PANAPARK Free Zone, and the Panama Canal. Under the MoU, both parties will collaborate to deliver a high-caliber edition of the World FZO World Congress, that convenes decision-makers, freezone leaders, and investors from more than 100 countries, in addition to attracting major economic institutions from around the world. The event is expected to strengthen Panama's global standing as a hub for trade and logistics and enhance its visibility on the international investment map. H.E. Dr. AlZarooni, said: 'World FZO is committed to forging strategic partnerships that enhance the role of freezones as drivers of global growth, based on the importance of developing platforms for international dialogue and cooperation to keep up with the major shifts taking place in the global economy. Our cooperation with the government of Panama represents a key milestone in our efforts to outreach to Latin American markets and strengthen cooperation with governments and economic institutions in this vital region.' H.E. Julio Moltó, said: 'Hosting the Congress represents a strategic step that highlights Panama's position as a global investment gateway and opens new prospects for regional cooperation, technology, and investment. We are committed to providing all necessary elements to ensure the success of this crucial event, in cooperation with the Organization. We value our partnership with World FZO and look forward to leveraging its extensive experience in the development and administration of freezones internationally, which will enhance the competitiveness of Panama's business environment and open our economy to global markets.' This announcement comes as preparations continue for the 11th World FZO Congress, set to take place in Hainan province, China, from 10–12 October 2025, held with the Hainan International Economic Development Bureau. The back-to-back hosting of the Congress in both China and then Panama reflects the growing momentum of the World FZO on the international stage. The World FZO World Congress is the world's premier gathering of freezone leaders, government officials, investors, and trade experts. It gathers more than 1,500 delegates from over 100 countries, bringing together a select group of decision-makers, and high-level representatives from global industry, trade, and investment sectors. Source: AETOSWire


Medscape
25 minutes ago
- Medscape
GLP-1 Agonists for Type 2 Diabetes Reduce Psoriasis, HS Risk
TOPLINE: Treatment with glucagon like peptide 1 receptor agonist (GLP-1 RA) medications was associated with a lower risk of being diagnosed with hidradenitis suppurativa (HS) or psoriasis, in a study of patients with type 2 diabetes (T2D). METHODOLOGY: Researchers assessed 74,910 patients (mean age, 65 years; 56% women; 45% White and 23% Black individuals) with T2D from the All of Us Database between May 2018 and October 2023. Of all patients, 19.5% received GLP-1 RAs. The primary outcomes of the study were risks for HS and psoriasis, adjusted for effects on control of diabetes and weight loss. TAKEAWAY: Overall, 1601 patients had psoriasis (mean age, 68 years; 56.4% women; 62.4% White and 12.2% Black individuals), and 601 had HS (mean age, 55 years; 77.2% women; 32.9% White and 41.3% Black individuals). Patients treated with GLP-1 RAs showed a significantly lower risk for a future diagnosis of HS (adjusted odds ratio [OR], 0.61; P < .001) than those who were not treated with GLP-1 RAs. GLP-1 RA treatment was also associated with a significant reduction in the risk for a future diagnosis of psoriasis (adjusted OR, 0.41; P < .001). The average time from T2D diagnosis to a diagnosis of HS was 3.98 years and 3.44 years to a diagnosis of HS. IN PRACTICE: 'These findings support a protective effect against HS and psoriasis in patients with T2DM taking GLP-1 RAs independent of weight loss, smoking status, or glycemic control,' the study authors wrote. Based on these findings, they added, 'future research should focus on prospective studies exploring the use of GLP-1 RAs as therapeutic tools to treat HS or psoriasis, prevent disease progression, and evaluate their effect in patients without diabetes.' SOURCE: The study was led by Lauren M. Ching, Georgetown University School of Medicine, Washington, DC, and was published online on July 23, 2025, in JAAD International. LIMITATIONS: Limitations included variance in data harmonization across sites, lack of disease severity information, and selection bias. DISCLOSURES: The study did not receive any funding. One author reported receiving financial aids as an investigator, consultant, and speaker from AbbVie, BMS, Eli Lilly, and various other drug companies. All other authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.